Arix Says Latest Equity Raising May Be Last For Some Time As Exit Options Loom
Executive Summary
Arix Bioscience's £87m equity raising brings to £250m the amount it has raised for incubating life sciences start-ups – but it might be the last for a while if portfolio 'exits' start generating cash, its CEO tells Scrip.
You may also be interested in...
IP Commercializer PureTech's CEO Outlines 2018 Roadmap After Financing
Daphne Zohar tells Scrip PureTech will use $100m placing to develop Boston-based group's growth-stage affiliates and advance its "BIG" proprietary pipeline of brain-immune-gut assets.
Arix And China's Fosun Ink A Strategic Partnership
A new strategic partnership has been forged between Arix Bioscience and China's Fosun International to develop new business opportunities in China.
Arix To Nurture Next Generation Biotechs After UK IPO
The supply of "permanent" capital and the desire to be involved operationally in new life science companies are some of the aims of Arix Bioscience, a UK company aiming to float on the London Stock Exchange, possibly by the end of this month.